Barclays
LUMO

Barclays’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Barclays’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-300
Closed -$13K – 7453
2018
Q2 		$13K Sell
300
-111
-27% -$5.08K ﹤0.01% 6424
2018
Q1 		$27K Buy
411
+155
+61% +$11K ﹤0.01% 6304
2017
Q4 		$19K Sell
256
-111
-30% -$9.18K ﹤0.01% 6316
2017
Q3 		$34K Buy
+367
New +$28.1K ﹤0.01% 5553

Other funds holding LUMO

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
IFG
Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's LUMO Position: Q1 2020 in Review

Barclays sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 1 share.

Barclays first reported a position in LUMO in Q2 2013 and held it in 27 quarters. The position peaked at $8.31M in Q1 2015. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

  • Barclays reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 1 Lumos Pharma, Inc. Common Stock share in Q1 2020.
  • Barclays first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Barclays's Lumos Pharma, Inc. Common Stock position peaked at $8.31M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.